Mesoblast Ltd., of Melbourne, Australia, and Boston Children's Hospital, the pediatric teaching hospital of Harvard University, said they've gained FDA approval for starting a 24-patient trial combining Mesoblast's allogeneic mesenchymal precursor cells (MPCs) with corrective heart surgery in children under the age of 5 with hypoplastic left heart syndrome (HLHS). The trial is sponsored and funded by the hospital with support from the Bulens and Capozzi Foundation and the Ethan Lindberg Foundation.